Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line
1991

Different mechanisms of drug resistance in breast cancer cells

publication Evidence: moderate

Author Information

Author(s): C.W. Taylor, W.S. Dalton, P.R. Parrish, M.C. Gleason, W.T. Bellamy, F.H. Thompson, D.J. Roe, J.M. Trent

Primary Institution: Arizona Cancer Center, University of Arizona

Hypothesis

The study investigates the mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line.

Conclusion

The two drug resistant cell lines have different mechanisms of decreased drug accumulation.

Supporting Evidence

  • MCF7/D40 cells show a classic multi-drug resistance phenotype with P-glycoprotein expression.
  • MCF7/Mitox cells do not express P-glycoprotein but still show decreased drug accumulation.
  • Both resistant cell lines have enhanced drug efflux compared to the parental MCF7 cell line.

Takeaway

Some breast cancer cells can become resistant to drugs, and this study found that two types of resistant cells use different ways to avoid the drugs.

Methodology

The study involved selecting drug resistant variants of the MCF7 cell line through chronic exposure to doxorubicin and mitoxantrone, followed by various assays to measure drug accumulation and resistance.

Statistical Information

P-Value

p<0.05

Confidence Interval

(32.1-59.0), (25.5-56.8), (35.0-47.6)

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication